tregalizumab   Click here for help

GtoPdb Ligand ID: 9864

Synonyms: BT-061 | hB-F5
Immunopharmacology Ligand
Compound class: Antibody
Comment: Tregalizumab (BT-061) is an anti-CD4 monoclonal antibody that was developed by Biotest Ag as a potential anti-rheumatoid arthritis therapy [4].
1. Humblet-Baron S, Baron F. (2015)
Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061).
Immunol Cell Biol, 93 (4): 321-2. [PMID:25666094]
2. König M, Rharbaoui F, Aigner S, Dälken B, Schüttrumpf J. (2016)
Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells.
Front Immunol, 7: 11. [PMID:26834751]
3. van Vollenhoven RF, Keystone EC, Strand V, Pacheco-Tena C, Vencovský J, Behrens F, Racewicz A, Zipp D, Rharbaoui F, Wolter R et al.. (2018)
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.
Ann Rheum Dis, 77 (4): 495-499. [PMID:29343509]
4. Wijdenes J. (2004)
Humanized anti-cd4 antibody with immunosuppressive properties.
Patent number: WO2004083247 A1. Assignee: Biotest Ag. Priority date: 21/03/2003. Publication date: 30/09/2004.